



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: July 25, 2007

By:

Rena lov

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Karl G. CSAKY et al.

APPLICATION No.: 10/588,884

FILED: August 9, 2006

INT'L APPLICATION No.: PCT/US2004/004142

FILED: FEBRUARY 12, 2004

FOR: **THERAPEUTIC ADMINISTRATION OF
THE SCRAMBLED ANTI-ANGIOGENIC
PEPTIDE C16Y**

EXAMINER: Unassigned

ART UNIT: 1654

CONFIRMATION No.: 8820

ATTY. DKT. No.: 41743.8005.US00

**Supplemental Information Disclosure Statement
Within Three Months of Application Filing or
Before First Action – 37 C.F.R. § 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references are enclosed:
 - ☒ All cited references
 - ☐ References marked by asterisks
 - ☐ The following:
- ☐ Copies of the following references can be found in parent U.S. Application No. :
 - ☐ All cited references
 - ☐ References marked by asterisks
 - ☐ The following:
- ☐ This application was filed after 30 June 2003 and no copies of U.S. patents nor published applications are enclosed (See Notice of Deputy Commissioner Kunin on 11 July 2003).
- ☐ The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.
 - ☐ All cited references
 - ☐ References marked by ampersands
 - ☐ The following:

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

- ☐ Applicant further submits that no fee is due in light of the following certification under 37 C.F.R. § 1.97(e) (check only one):
- ☐ In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
- ☐ In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP



Patrick D. Morris, Ph.D.
Registration No. 53,351

Date: July 25, 2007

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900
Fax: (206) 332-7198

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/588,884
			Confirmation Number	8820
			Filing Date	August 9, 2006
			First Named Inventor	Karl G. Csaky
			Group Art Unit	1654
			Examiner Name	Unassigned
Sheet	1	of	Attorney Docket No.	41743.8005.US00

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	A1	Ciulla, T.A. 2003. Recent advances in the treatment of exudative age-related macular degeneration, including transpupillary thermotherapy. <i>Acta Ophthalmol Scand</i> 81:103-104.	
	A2	Grant, D.S., et al. 1989. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures <i>in vitro</i> . <i>Cell</i> 58:933-943.	
	A3	Iwamoto, Y., et al. 1987. YIGSR a pentapeptide from the B1 chain of laminin inhibits tumor cell metastases. <i>Science</i> 238:1132-1134.	
	A4	Kuratomi, Y., et al. 2002. Laminin γ 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. <i>Br J Cancer</i> 86:1169-1173.	
	A5	Kuratomi, Y., et al. 1999. Identification of metastasis-promoting sequences in the mouse laminin α -1 chain. <i>Exp Cell Res</i> 249:386-395.	
	A6	Malinda, K. M., et al. 1999. Identification of laminin α -1 and β -1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. <i>FASEB J</i> 13:53-62.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/588,884
				Confirmation Number	8820
				Filing Date	August 9, 2006
				First Named Inventor	Karl G. Csaky
				Group Art Unit	1654
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket No.	41743.8005.US00

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	A7	Ponce, M. L., et al. 1999. Identification of endothelial cell binding sites on the laminin γ -1 chain. Circ Res 84:688-694.		
	A8	Ponce, M. L., Nomizu, M., Kleinman, H. K. 2001. An angiogenic laminin site and its antagonist bind through the $\alpha v \beta 3$ and $\alpha 5 \beta 1$ integrins. FASEB J 15:1389-1397.		
	A9	Ponce, M. L., Kleinman, H. K. 2003a. Identification of Redundant Angiogenic sites in laminin $\alpha 1$ and $\gamma 1$ chains. Exp Cell Res 285:189-195.		
	A10	Ponce, M.L., et al. 2003b. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res 63:5060-5064.		
	A11	Powell, S.K., Kleinman, H.K. 1997. Neuronal laminins and their cellular receptors. Int J Biochem Cell Biol 29:401-414.		
	A12	Pupa, S.M., Menard, S., Forti, S., Tagliabue, E. 2002. New insights into the role of extracellular matrix during tumor onset and progression. J Cellul Physiol 192:259-267.		
	A13	Sakamoto, N., Iwahana, M., Tanaka, N.G., Osada, Y. 1991. Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CD PGYIGSR-NH2. Cancer Res 51:903-906.		
	A14	Varner, J.A., Cheresh, D.A. 1996. Tumor angiogenesis and the role of vascular cell integrin $\alpha v \beta 3$. Important Adv Oncol 69-87.		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	